Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for critically ill trauma patients
ACTRN12619001632189Phase 3Recruiting
- Sponsor
- Monash University
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised trial of epoetin alfa in Physical trauma and critical illness (2 arms), sponsored by Monash University. Primary endpoint: Composite of mortality and severe disability. Started Nov 2020; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
Physical traumacritical illness
Beyond the preview
Go deeper on ACTRN12619001632189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001632189.